Definium Therapeutics (DFTX) Share-based Compensation (2019 - 2026)
Definium Therapeutics (DFTX) reported Share-based Compensation of $7.1 million for Q1 2026, up 108.17% year-over-year from $3.4 million in Q1 2025, and up 27.33% on a QoQ basis from $5.6 million in Q4 2025.
Definium Therapeutics (DFTX) has 8 years of Share-based Compensation data on file, last reported at $7.1 million in Q1 2026.
- Quarterly Share-based Compensation rose 108.17% year-over-year to $7.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.8 million (up 42.95% YoY) and the FY2025 annual result came in at $20.1 million, up 18.82% from the prior year.
- Share-based Compensation grew to $7.1 million in Q1 2026 per DFTX's latest filing, from $5.6 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $7.1 million in Q1 2026 and bottomed at $1.4 million in Q4 2022.
- The 5-year median for Share-based Compensation is $4.0 million (2024), against an average of $4.3 million.
- Peak annual rise in Share-based Compensation reached 196.48% in 2022, while the deepest fall reached 87.11% in 2022.
- Tracing DFTX's Share-based Compensation over 5 years: stood at $1.4 million in 2022, then soared by 144.55% to $3.4 million in 2023, then gained by 17.47% to $4.0 million in 2024, then surged by 41.69% to $5.6 million in 2025, then climbed by 27.33% to $7.1 million in 2026.
- Per Business Quant, the three latest DFTX Share-based Compensation figures stand at $7.1 million (Q1 2026), $5.6 million (Q4 2025), and $5.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Definium Therapeutics | 2.42 Bn | 2.06 Bn | - | 7.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.13 Mn |
| Mar 31, 2026 | 7.13 Mn |
| Dec 31, 2025 | 5.60 Mn |
| Dec 31, 2025 | 5.60 Mn |
| Sep 30, 2025 | 5.82 Mn |
| Sep 30, 2025 | 5.82 Mn |
| Jun 30, 2025 | 5.25 Mn |
| Jun 30, 2025 | 5.25 Mn |
| Mar 31, 2025 | 3.43 Mn |
| Mar 31, 2025 | 3.43 Mn |
| Dec 31, 2024 | 3.95 Mn |
| Dec 31, 2024 | 3.95 Mn |
| Sep 30, 2024 | 3.84 Mn |
| Sep 30, 2024 | 3.84 Mn |
| Jun 30, 2024 | 5.43 Mn |
| Jun 30, 2024 | 5.43 Mn |
| Mar 31, 2024 | 3.69 Mn |
| Mar 31, 2024 | 3.69 Mn |
| Dec 31, 2023 | 3.37 Mn |
| Dec 31, 2023 | 3.37 Mn |
| Sep 30, 2023 | 4.23 Mn |
| Sep 30, 2023 | 4.23 Mn |
| Jun 30, 2023 | 3.84 Mn |
| Jun 30, 2023 | 3.84 Mn |
| Mar 31, 2023 | 3.75 Mn |
| Mar 31, 2023 | 3.75 Mn |
| Dec 31, 2022 | 1.38 Mn |
| Dec 31, 2022 | 1.38 Mn |
| Sep 30, 2022 | 4.29 Mn |
| Sep 30, 2022 | 4.29 Mn |
| Jun 30, 2022 | 4.25 Mn |
| Jun 30, 2022 | 4.25 Mn |
| Mar 31, 2022 | 3.79 Mn |
| Mar 31, 2022 | 3.79 Mn |
| Dec 31, 2021 | 4.34 Mn |
| Dec 31, 2021 | 4.34 Mn |
| Sep 30, 2021 | 4.11 Mn |
| Sep 30, 2021 | 4.11 Mn |
| Jun 30, 2021 | 32.99 Mn |
| Jun 30, 2021 | 32.99 Mn |
| Mar 31, 2021 | 1.28 Mn |
| Mar 31, 2021 | 1.28 Mn |
| Dec 31, 2020 | 9.58 Mn |
| Dec 31, 2020 | 9.58 Mn |
| Jun 30, 2020 | -30,000.00 |
| Jun 30, 2020 | -30,000.00 |
| Mar 31, 2020 | 2.14 Mn |
| Mar 31, 2020 | 2.14 Mn |
| Dec 31, 2019 | 73,000.00 |
| Dec 31, 2019 | 73,000.00 |